media – Page 619 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration

"This collaboration is the first for Harpoon and highlights the high level of industry interest in best-in-class platform technologies. We are excited about partnering with AbbVie to help generate novel T-cell engagers for the treatment of cancer based on the combination of T-cell receptors with TriTACs," said Jerry McMahon, Ph.D., chief executive officer, Harpoon Therapeutics.
- Source: finance.yahoo
- 684
- October 23, 2017
AbbVie Market Views T-cell recruiting biologic
Britain backs GSK’s gene therapy for ‘bubble boy’ syndrome

Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment.
- Source: reuters
- 820
- October 23, 2017
ADA-SCID Company Insight gene Market Views NICE
Drug delivery devices market in India to reach $510m by 2023

The drug delivery devices market in India is expected to rise at a compound annual growth (CAGR) of 3.1% from $411m in 2016 to $510m by 2023, according to a report by GlobalData.
- Source: medicaldevice-network
- 392
- October 23, 2017
drug delivery devices India Market Views
‘Handful of changes’ make cancer

British scientists have worked out how many changes it takes to transform a healthy cell into a cancer.
- Source: bbc
- 804
- October 23, 2017
cancer herceptin inhibitor tumour
China to adjust registration management for drugs and medical devices

To promote the adjustment of industrial structure and technological innovation in the drug and medical device sector, the Communist Party of China’s Central Committee and the State Council jointly released a guideline on the reform of the review and approval system, which came into effect on October 8, 2017.
- Source: china-briefing
- 1,193
- October 23, 2017
CFDA drug medical device Policy
Guidance for Visiting Foreign Clients (Ⅰ)

In the age of e-commerce, there are multiple ways to develop potential client relationships online but site visits have been proven to be the most effective method. Nowadays, many forward-thinking companies are going global with great achievements but, in contrast to these early adopters, there are those companies who are still waiting on the sidelines, mostly due to a lack of expertise and experience. This is why Ddu has prepared a list of our tried and trusted methods for visiting and dealing with foreign clients.
- Source: Ddu
- 1,190
- October 20, 2017
clients Ddu College
Australia’s second largest state edges towards permitting euthanasia

The parliament of Australia’s second largest state passed legislation on Friday to allow terminally ill patients to seek medical help to end their lives, a bill that is expected to act as a catalyst for the rest of the country to adopt similar laws.
- Source: reuters
- 559
- October 20, 2017
catalyst euthanasia Market Views Policy
‘Synthetic gene circuit’ may improve effectiveness of cancer immunotherapy

Synthetic gene circuits that only trigger powerful, tumor-specific immune responses when they detect certain disease markers may help immunotherapies to fight cancer more effectively, according to a new study.
- Source: medicalnewstoday
- 691
- October 20, 2017
cancer immunotherapies Synthetic gene
Broken Bones Mended With Stem Cells And Plastic

New bone tissue grown from patients' own stem cells that attach themselves to an implanted, rigid lightweight plastic "scaffolding" which gradually degrades and is replaced as new bone grows, could soon be healing shattered limbs, according to a new research report.
- Source: medicalnewstoday
- 676
- October 20, 2017
bone Researches stem cells
Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Eli Lilly and Company (LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer immune response.
- Source: Finance
- 663
- October 20, 2017
immune Market Views mRNA vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.